



Acylimine mediated N–N bond cleavage of pyrazolidinediones and subsequent conversion to dihydropyrimidinediones and malonamides

Yong Gong,^{a,*} Mark J. Bausch^b and Linhua Wang^b

^aDepartment of Medicinal Chemistry, Aventis Pharmaceuticals, Bridgewater, NJ 08807, USA

^bDepartment of Chemistry and Biochemistry, Southern Illinois University, Carbondale, IL 62901, USA

Received 9 October 2000; accepted 23 October 2000

Abstract—Acylimines **3** were identified as intermediates in the fluorenyl assisted N–N bond cleavage of pyrazolidinediones **1**. Subsequent conversion of **3** to dihydropyrimidinediones **4** and malonamides **7–10** is described. © 2000 Published by Elsevier Science Ltd.

Reductive cleavage of the N–N bond under strongly reducing conditions, e.g. metal (Li, Na) in ammonia, Raney Nickel, or SmI₂, can provide an efficient synthetic route to amino/acylamino and diamino derivatives.¹ This type of functionality can also be accessed by base promoted N–N bond cleavage of diazetidinones and acyl hydrazines.² Acylimines, on the other hand, are valuable, reactive reagents in the organic synthesis³ which have served as building blocks for various amino acid derivatives,⁴ including the Taxol A-ring side-chain,⁵ and β-amido aldehydes.⁶ Acylimines have also been invoked as intermediates in the ring transformation of diazetidinones,⁷ indazolones,⁸ and urazoles.⁹ However, there is no direct empirical evidence for their formation during these reactions.

Previously, we reported an efficient insertion of fluorenylene into urazoles to provide the corresponding triazinanediones.¹⁰ In this letter, we describe the reaction of 9-bromofluorene with pyrazolidinediones leading to the initial formation of stable acylimine intermediates which can be converted into cyclic insertion products or to acyclic acylamino/amino derivatives, depending on the reaction conditions.


Keywords: acylimine; cleavage reactions; cyclization; fluorenes; ring transformations.

* Corresponding author. Fax: 1-908-231-3577; e-mail: yong.gong@aventis.com


In an initial experiment, reaction of 9-bromofluorene (9-BrFl) with the potassium salt of **1a** (**1a-K**), generated in situ from 4,4-diethyl-1-methylpyrazolidine-3,5-dione and potassium *t*-butoxide (KOCMe₃), provided three products (Scheme 1). These products were separated and characterized as the substitution product, fluorenyl pyrazolidinedione **2a** (5%), the ring opening product, acylimine **3a** (65%) and the insertion product pyrimidinedione **4a** (12%), respectively.^{11,12}

The isolation of acylimine **3a** is significant, in that, to our knowledge, this is the first example of a stable acylimine being generated from N–N bond cleavage of an acyl hydrazine. Our mechanistic proposal for the formation of acylimine **3a** is also illustrated in Scheme 1. Compound **2a**, the initial product from the reaction, undergoes proton exchange with unreacted anion **1a-K** to generate fluorenyl anion **2a-K** and pyrazolidinedione **1a**. Anion **2a-K** then promotes the N–N bond cleavage to give acylimine anion **3a-K**. Proton exchange from **1a** to **3a-K** forms acylimine **3a**, and regenerates anion **1a-K**. The isolation of the insertion product **4a** as a minor component of the reaction mixture reflects a relatively unfavorable competition reaction, in which the acylimine anion **3a-K** cyclizes to anion **4a-K**, and then is protonated by **1a**.


Schemes 2–6 illustrate some simple manipulations of this basic reaction system which provide a variety of products. When pyrazolidinedione **1b** (Scheme 2) was first treated with KOCMe₃, and then allowed to react with 9-BrFl and the crude products further treated with



Scheme 1.




Scheme 2.




Scheme 3.

ethanol, malonamide **5**, the addition product of EtOH to the corresponding acylimine, was the major product (56%), along with substitution product **2b** (24%) and insertion product **4b** (5%).

However, when **2b** was subsequently treated with KOCMe_3 and the reaction quenched with aqueous NH_4Cl , **4b** was obtained in high yield (91%), presumably, via the process of deprotonation, cleavage, cyclization, and protonation, as discussed above.



Scheme 4.



Scheme 5.

One-pot insertion of fluorenylene into the N–N bond is outlined in Scheme 3. Pyrazolidinedione **1c** was first treated with KOCMe₃ and then allowed to react with 9-BrFl. The resulting reaction mixture was further treated with KOCMe₃ before being quenched with NH₄Cl/H₂O to give, on isolation, the insertion product **4c** (79%).


Cycloaddition of acylimine **3a** with 1,1-dimethoxyethylene³ (Scheme 4) produced dihydrooxazine **6**, which was hydrolyzed under mild conditions to ester **7**. Further hydrolysis of **7** gave acid **8**. Coupling of **8** with glycylglycine methyl ester (GGOMe) yielded the novel peptide product **9**.

Acylimine **3a** is sensitive to moisture and is hydrolyzed to malonamide **10a** and 9-fluorenone upon standing (Scheme 5). This observation led us to explore the practicality of an one-pot approach to 2,2,*N*-trisubstituted malonamides (Scheme 6). 1,5,5-Trisubstituted pyrazolidinediones (**1a–d**) were treated with KOCMe₃, and allowed to react with 9-BrFl. The resulting reaction mixtures were then simply exposed to moisture. Gratifyingly, 2,2,*N*-trisubstituted malonamides (**10a–d**) were obtained in good yields (59–65%).¹³ This overall process can be considered as reductive cleavage of N–N bond in pyrazolidinedione **1** with the reducing agent 9-BrFl being oxidized to 9-fluorenone.¹⁴

In conclusion, acylimines have been isolated for the first time as products from N–N bond cleavage of pyrazolidinediones. Further useful transformations of these intermediates to dihydropyrimidinediones and 2,2,*N*-trisubstituted malonamides have been developed.

Acknowledgements

Y.G. thanks Dr. D. G. McGarry for his suggestions in the preparation of this manuscript.



- | | |
|--|-----|
| a. R ¹ = Me, R ² = R ³ = Et | 65% |
| b. R ¹ = Ph, R ² = R ³ = -(CH ₂) ₄ - | 59% |
| c. R ¹ = R ² = Ph, R ³ = Et | 58% |
| d. R ¹ = R ² = R ³ = Me | 61% |

Scheme 6.

References

- (a) Song, J.; Hesse, M. *Tetrahedron* **1993**, *49*, 6797–6804; (b) Grabowski, S.; Prinzbach, H. *Tetrahedron Lett.* **1996**, *37*, 7951–7954; (c) Itoh, N.; Matsuyama, H.; Yoshida, M.; Kamigata, N.; Iyoda, M. *Heterocycles* **1995**, *413*, 415–418; (d) Barluenga, J.; Fernandez-Mari, F.; Viado, A. L.; Aguilar, E.; Olano, B.; Garcia-Granda, S.; Moyarubiera, C. *Chem. Eur. J.* **1999**, *5*, 883–896; (e) Zupancic, S.; Svete, J.; Stanovnic, B. *J. Heterocycl. Chem.* **1999**, *36*, 607–610; (f) Okitsu, O.; Oyamada, H.; Furuta, T.; Kobayashi, S. *Heterocycle* **2000**, *52*, 1143–1162; (g) Overman, L. E.; Rogers, B. N.; Tellew, J. E.; Trenkle, W. C. *J. Am. Chem. Soc.* **1997**, *119*, 7159–7160.
- (a) Endo, Y.; Uchida, T.; Shudo, K. *Tetrahedron Lett.* **1997**, *38*, 2113–2116; (b) Endo, Y.; Uchida, T.; Yamaguchi, K. *Heterocycles* **2000**, *53*, 151–158; (c) Fahr, E.; Fischer, W. *Tetrahedron Lett.* **1967**, 3291–3293.
- Weinreb, S. M.; Scola, P. M. *Chem. Rev.* **1989**, *89*, 1524–1534.
- Beller, M.; Echert, M. *Angew. Chem., Int. Ed.* **2000**, *39*, 1011–1027.
- Swindell, C. S.; Tao, M. *J. Org. Chem.* **1993**, *58*, 5889–5891.
- Gizecki, P.; Dhal, R.; Toupet, L.; Dujardin, G. *Org. Lett.* **2000**, *2*, 585–588.
- (a) Taylor, E. C.; Clemens, R. J.; Davies, H. M. L.; Haley, N. F. *J. Am. Chem. Soc.* **1981**, *103*, 7659–7660; (b) Taylor, E. C.; Davies, H. M. L.; Hinkle, J. S. *J. Org. Chem.* **1986**, *51*, 1530–1536.
- Baiocchi, L.; Picconi, G. *Tetrahedron Lett.* **1986**, *27*, 5255–5256.
- Adam, W.; Grabowski, S.; Hinz, R. F.; Luccini, V.; Peters, E.-M.; Peters, K.; Rebollo, H.; von Schnering, H. G. *Chem. Ber.* **1987**, *120*, 2075–2079.
- Robinson, P. D.; Gong, Y.; Bausch, M. J. *Acta Crystallogr., Sect. C* **1996**, *52*, 2337–2340.
- 2a**: mp 138–139°C; IR (KBr) 1706, 1682 cm⁻¹; ¹H NMR (CDCl₃) δ 7.29–7.70 (m, 8H), 6.82 (s, 1H), 3.38 (s, 3H), 1.68 (m, 4H), 0.83 (t, *J* = 7.5 Hz, 6H); ¹³C NMR (CDCl₃) δ 174.0, 172.8, 141.8, 141.0, 129.8, 127.9, 55.3, 31.0, 27.4, 8.9. Anal. calcd for C₂₁H₂₂N₂O₂: C, 75.42; H, 6.63; N, 8.38. Found: C, 75.08; H, 6.65; N, 8.42. **3a**: IR (KBr) 3366, 1713, 1662 cm⁻¹; ¹H NMR (CDCl₃) δ 7.23–7.69 (m, 9H), 2.90 (d, *J* = 4.5 Hz, 3H), 2.05 (m, 4H), 0.93 (t, *J* = 7.5 Hz, 6H); ¹³C NMR (CDCl₃) δ 189.3, 171.7, 143.3, 134.7, 133.6, 128.5, 125.6, 120.4, 105.6, 61.4, 28.9, 26.4, 9.7. EI MS *m/e* 334. **4a**: mp 300–301°C; IR (KBr) 3201, 1670, 1626 cm⁻¹; ¹H NMR (CDCl₃) δ 7.33–7.68 (m, 8H), 6.20 (s, 1H), 2.46 (s, 3H), 2.11 (m, 4H), 1.13 (t, *J* = 7.5

- Hz, 6H); ^{13}C NMR (CDCl_3) δ 170.9, 170.3, 144.1, 139.2, 130.9, 129.2, 123.9, 120.7, 79.7, 55.5, 31.9, 29.3, 11.0. Anal. calcd for $\text{C}_{21}\text{H}_{22}\text{N}_2\text{O}_2$: C, 75.42; H, 6.63; N, 8.38. Found: C, 75.34; H, 6.62; N, 8.38.
12. For X-ray crystal structure of **4a**, see: Gong, Y.; Robinson, P. D.; Bausch, M. J. *Acta Crystallogr.*, Sect. C **1996**, 52, 2081–2084.
13. Preparation of tetrasubstituted malonamides from decarbonylation of barbituric acids was reported recently: Jursic, B. S. *Tetrahedron Lett.* **2000**, 41, 5325–5328.
14. With fluorenyl pyrazolidinediones (**2**) and dihydropyrimidinediones (**4**) as the by-products.